{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T12:10:41Z","timestamp":1791720641701,"version":"4.3.4"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["RO1-DK92179"],"award-info":[{"award-number":["RO1-DK92179"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R03-DK107402"],"award-info":[{"award-number":["R03-DK107402"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01-DK111378"],"award-info":[{"award-number":["R01-DK111378"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Palumbo Foundation"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.coph.2017.09.008","type":"journal-article","created":{"date-parts":[[2017,11,5]],"date-time":"2017-11-05T23:13:01Z","timestamp":1509923581000},"page":"80-86","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"C","title":["Modulating bile acid pathways and TGR5 receptors for treating liver and GI diseases"],"prefix":"10.1016","volume":"37","author":[{"given":"Harmeet","family":"Malhi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Camilleri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2017.09.008_bib0005","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1113\/jphysiol.2014.271155","article-title":"Neuro-humoral signalling by bile acids and the TGR5 receptor in the gastrointestinal tract","volume":"592","author":"Bunnett","year":"2014","journal-title":"J Physiol"},{"key":"10.1016\/j.coph.2017.09.008_bib0010","first-page":"593","article-title":"Relationships between ion and water movement in the human jejunum, ileum and colon during perfusion with bile acids","volume":"45","author":"Wingate","year":"1973","journal-title":"Clin Sci Mol Med"},{"key":"10.1016\/j.coph.2017.09.008_bib0015","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1136\/gut.16.11.894","article-title":"Bile acids and colonic motility in the rabbit and the human","volume":"16","author":"Kirwan","year":"1975","journal-title":"Gut"},{"key":"10.1016\/j.coph.2017.09.008_bib0020","doi-asserted-by":"crossref","first-page":"G443","DOI":"10.1152\/ajpgi.00194.2001","article-title":"The proximal colonic motor response to rectal mechanical and chemical stimulation","volume":"282","author":"Bampton","year":"2002","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.coph.2017.09.008_bib0025","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.1210\/en.2015-1321","article-title":"Bile acids trigger GLP-1 release predominantly by accessing basolaterally located G protein-coupled bile acid receptors","volume":"156","author":"Brighton","year":"2015","journal-title":"Endocrinology"},{"key":"10.1016\/j.coph.2017.09.008_bib0030","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1177\/030006058301100211","article-title":"Treatment of constipation with chenodeoxycholic acid","volume":"11","author":"Bazzoli","year":"1983","journal-title":"J Int Med Res"},{"key":"10.1016\/j.coph.2017.09.008_bib0035","first-page":"661","article-title":"Effect of molecular structure on bile acid-induced alterations in absorptive function, permeability, and morphology in the perfused rabbit colon","volume":"94","author":"Chadwick","year":"1979","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.coph.2017.09.008_bib0040","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1113\/jphysiol.2013.252544","article-title":"Ursodeoxycholic acid attenuates colonic epithelial secretory function","volume":"591","author":"Kelly","year":"2013","journal-title":"J Physiol"},{"key":"10.1016\/j.coph.2017.09.008_bib0045","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1007\/s10620-006-9090-8","article-title":"Taurodeoxycholate modulates apical Cl\u2212\/OH\u2212 exchange activity in Caco2 cells","volume":"52","author":"Alrefai","year":"2007","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.coph.2017.09.008_bib0050","doi-asserted-by":"crossref","first-page":"C447","DOI":"10.1152\/ajpcell.00416.2012","article-title":"Chenodeoxycholic acid stimulates Cl\u2212 secretion via cAMP signaling and increases cystic fibrosis transmembrane conductance regulator phosphorylation in T84 cells","volume":"305","author":"Ao","year":"2013","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.coph.2017.09.008_bib0055","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/sj.bjp.0702615","article-title":"Involvement of serotonin and calcium channels in the intestinal fluid secretion evoked by bile salt and cholera toxin","volume":"127","author":"Peregrin","year":"1999","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.coph.2017.09.008_bib0060","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/j.1365-2982.2010.01487.x","article-title":"Expression and function of the bile acid receptor GpBAR1 (TGR5) in the murine enteric nervous system","volume":"22","author":"Poole","year":"2010","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.coph.2017.09.008_bib0065","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1053\/j.gastro.2012.09.055","article-title":"The receptor TGR5 mediates the prokinetic actions of intestinal bile acids and is required for normal defecation in mice","volume":"144","author":"Alemi","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2017.09.008_bib0070","article-title":"Bile acid deficiency in subgroup of irritable bowel syndrome with constipation based on serum and fecal biomarkers","author":"Vijayvargiya","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.coph.2017.09.008_bib0075","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1053\/j.gastro.2010.07.052","article-title":"Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis","volume":"139","author":"Rao","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2017.09.008_bib0080","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1038\/ajg.2011.285","article-title":"Effects of A3309, an ileal bile acid transporter inhibitor, on colonic transit and symptoms in females with functional constipation","volume":"106","author":"Wong","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.coph.2017.09.008_bib0085","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1038\/ajg.2011.162","article-title":"A randomized placebo-controlled phase IIb trial of A3309, a bile acid transporter inhibitor, for chronic idiopathic constipation","volume":"106","author":"Chey","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.coph.2017.09.008_bib0090","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(17)30523-1","article-title":"Determining an optimal clinical dose of elobixibat, a novel inhibitor of the ileal bile acid transporter, in Japanese patients with chronic constipation: a phase II, multicenter, double-blind, placebo-controlled randomized clinical trial","author":"Nakajima","year":"2017","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.coph.2017.09.008_bib0095","doi-asserted-by":"crossref","first-page":"S1315","DOI":"10.1016\/S0016-5085(17)34375-5","article-title":"NGM282, variant of FGF19, is a gastric and colonic prokinetic and stimulates bowel function in patients with functional constipation: phase 1B, two-dose, placebo-controlled study","volume":"152","author":"Oduyebo","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2017.09.008_bib0100","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1136\/gutjnl-2015-309889","article-title":"Biomarkers for bile acid diarrhea in functional bowel disorder with diarrhea: a systematic review and meta-analysis","volume":"65","author":"Valentin","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.coph.2017.09.008_bib0105","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/apt.13193","article-title":"Randomised clinical trial: cholestyramine vs. hydroxypropyl cellulose in patients with functional chronic watery diarrhoea","volume":"41","author":"Fern\u00e1ndez-Ba\u00f1ares","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.coph.2017.09.008_bib0110","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1111\/apt.12684","article-title":"Systematic review: the management of chronic diarrhoea due to bile acid malabsorption","volume":"39","author":"Wilcox","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.coph.2017.09.008_bib0115","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/gutjnl-2013-305965","article-title":"Increased colonic bile acid exposure: a relevant factor for symptoms and treatment in IBS","volume":"64","author":"Bajor","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.coph.2017.09.008_bib0120","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/apt.13065","article-title":"Effect of colesevelam on faecal bile acids and bowel functions in diarrhoea-predominant irritable bowel syndrome","volume":"41","author":"Camilleri","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.coph.2017.09.008_bib0125","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.cgh.2009.10.020","article-title":"Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function","volume":"8","author":"Odunsi-Shiyanbade","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.coph.2017.09.008_bib0130","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/MEG.0000000000000541","article-title":"Long-term outcomes in patients diagnosed with bile-acid diarrhoea","volume":"28","author":"Lin","year":"2016","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.coph.2017.09.008_bib0135","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/apt.12999","article-title":"The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid","volume":"41","author":"Walters","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.coph.2017.09.008_bib0140","doi-asserted-by":"crossref","first-page":"e0147210","DOI":"10.1371\/journal.pone.0147210","article-title":"Changes in colonic bile acid composition following fecal microbiota transplantation are sufficient to control Clostridium difficile germination and growth","volume":"11","author":"Weingarden","year":"2016","journal-title":"PLOS ONE"},{"key":"10.1016\/j.coph.2017.09.008_bib0145","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1097\/MCG.0000000000000427","article-title":"Ursodeoxycholic acid inhibits Clostridium difficile spore germination and vegetative growth, and prevents the recurrence of ileal pouchitis associated with the infection","volume":"50","author":"Weingarden","year":"2016","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.coph.2017.09.008_bib0150","first-page":"7","article-title":"Complete microbiota engraftment is not essential for recovery from recurrent Clostridium difficile infection following fecal microbiota transplantation","author":"Staley","year":"2016","journal-title":"MBio"},{"key":"10.1016\/j.coph.2017.09.008_bib0155","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1053\/j.gastro.2017.01.055","article-title":"Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease","volume":"152","author":"Ch\u00e1vez-Talavera","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2017.09.008_bib0160","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary dholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2017.09.008_bib0165","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1053\/j.gastro.2009.01.003","article-title":"Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid","volume":"136","author":"Kuiper","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2017.09.008_bib0170","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/S0140-6736(17)30319-7","article-title":"Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study","volume":"389","author":"Hegade","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2017.09.008_bib0175","first-page":"263A","article-title":"NGM282, a novel variant of FGF-19, demonstrates biologic activity in primary biliary cirrhosis patients with an incomplete response to ursodeoxycholic acid: results of a phase 2 multicenter, randomized, double blinded, placebo controlled trial","volume":"62","author":"Mayo","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.coph.2017.09.008_bib0180","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/hep.24537","article-title":"Dual farnesoid X receptor\/TGR5 agonist INT-767 reduces liver injury in the Mdr2\u2212\/\u2212 (Abcb4\u2212\/\u2212) mouse cholangiopathy model by promoting biliary HCO3\u2212 output","volume":"54","author":"Baghdasaryan","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.coph.2017.09.008_bib0185","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2017.09.008_bib0190","series-title":"Presented at The International Liver Congress\u2122 Amsterdam, Netherlands, April 22","article-title":"NGM282, a novel variant of FGF19, significantly reduces hepatic steatosis and key biomarkers of NASH: results of a phase 2, multicenter, randomized, double-blinded, placebo controlled trial in biopsy-confirmed NASH patients","author":"Harrison","year":"2017"},{"key":"10.1016\/j.coph.2017.09.008_bib0195","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1172\/JCI76738","article-title":"Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease","volume":"125","author":"Jiang","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coph.2017.09.008_bib0200","doi-asserted-by":"crossref","first-page":"357ra122","DOI":"10.1126\/scitranslmed.aaf4823","article-title":"Inhibition of ileal bile acid uptake protects against nonalcoholic fatty liver disease in high-fat diet-fed mice","volume":"8","author":"Rao","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coph.2017.09.008_bib0205","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nm.3760","article-title":"Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance","volume":"21","author":"Fang","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.coph.2017.09.008_bib0210","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1172\/JCI64551","article-title":"The TGR5 receptor mediates bile acid-induced itch and analgesia","volume":"123","author":"Alemi","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coph.2017.09.008_bib0215","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/hep.26909","article-title":"Pruritus in cholestasis: facts and fiction","volume":"60","author":"Beuers","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.coph.2017.09.008_bib0220","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.gastro.2014.12.005","article-title":"Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid","volume":"148","author":"Hirschfield","year":"2015","journal-title":"Gastroenterology"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489217300681?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489217300681?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,5]],"date-time":"2019-10-05T16:50:20Z","timestamp":1570294220000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489217300681"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":44,"alternative-id":["S1471489217300681"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2017.09.008","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modulating bile acid pathways and TGR5 receptors for treating liver and GI diseases","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2017.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}